Brief: Enveric Biosciences Receives FDA Response And Streamlines Plans For EB-003 IND Submission
16/09/2025 14:30
Sept 16 (Reuters) - Enveric Biosciences Inc ENVB.O: ENVERIC BIOSCIENCES RECEIVES FDA RESPONSE AND STREAMLINES PLANS FOR EB-003 IND SUBMISSION ENVERIC BIOSCIENCES INC - EXPECTS TO FILE IND FOR EB-003 IN EARLY 2026 ENVERIC BIOSCIENCES INC - FDA RECOMMENDS ENVERIC PROCEED WITH IND APPLICATION FOR EB-003 Source text: ID:nBwPsncka Further company coverage: ENVB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003